Quince Therapeutics 公司宣布，其候选药物 Lam-001 在针对特发性肺纤维化（Ph-ILD）患者的二期a阶段临床试验中取得了积极结果。数据显示，治疗24周后，患者的六分钟步行距离（6MWD）实现了6740万米的显著改善，同时肺血管阻力（PVR）也降低了33.9%。
Quince Therapeutics 公司宣布，其候选药物 Lam-001 在针对特发性肺纤维化（Ph-ILD）患者的二期a阶段临床试验中取得了积极结果。数据显示，治疗24周后，患者的六分钟步行距离（6MWD）实现了6740万米的显著改善，同时肺血管阻力（PVR）也降低了33.9%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.